Skip to main content

Table 1 Distribution of the clinicopathological characteristics of all samples or Her2-amplified samples split into discovery and validation cohorts according to the Morisita index

From: An ecological measure of immune-cancer colocalization as a prognostic factor for breast cancer

Characteristics All subtypes (discovery) All subtypes (validation) Her2+ (discovery) HER2+ (validation)
Morisita high Morisita low P Morisita high Morisita low P Morisita high Morisita low P Morisita high Morisita low P
Number   316 170   377 139   42 34   37 20  
Follow up (months)   117.7 (4.9–120) 110.3 (4.2–120)   64.8 (0.3–120) 50.5 (1.9–120)   108.1 (21.2–120) 61.5 (6.8–120)   62.3 (1.8–120) 36.3 (10–88.4)  
Age, years   59.8 (27.6–86.1) 59.3 (21.9–83.4) 0.38 60.8 (30–92.1) 60.9 (26.4–96.3) 0.81 57 (28.4–80.6) 54.2 (21.9–71) 0.23 57.4 (33.6–87) 55.9 (35.9–87.2) 0.65
Death No 246 (77.8 %) 113 (66.5 %) 0.0074* 334 (88.6 %) 115 (82.7 %) 0.1 25 (59.5 %) 14 (41.2 %) 0.097 35 (94.6 %) 13 (65 %) 0.0063*
  Yes 64 (20.3 %) 53 (31.2 %)   43 (11.4 %) 24 (17.3 %)   14 (33.3 %) 19 (55.9 %)   2 (5.4 %) 7 (35 %)  
Size <2 cm 122 (38.6 %) 66 (38.8 %) 0.88 120 (31.8 %) 41 (29.5 %) 0.27 9 (21.4 %) 13 (38.2 %) 0.15 9 (24.3 %) 9 (45 %) 0.056
  >2 cm, <5 cm 177 (56 %) 97 (57.1 %)   226 (59.9 %) 80 (57.6 %)   30 (71.4 %) 17 (50 %)   24 (64.9 %) 7 (35 %)  
  >5 cm 17 (5.4 %) 7 (4.1 %)   29 (7.7 %) 17 (12.2 %)   3 (7.1 %) 4 (11.8 %)   3 (8.1 %) 4 (20 %)  
Node Neg (pN0) 153 (48.4 %) 84 (49.4 %) 0.85 180 (47.7 %) 57 (41 %) 0.19 19 (45.2 %) 10 (29.4 %) 0.23 15 (40.5 %) 9 (45 %) 0.78
  Pos (pN1-pN3) 163 (51.6 %) 86 (50.6 %)   193 (51.2 %) 80 (57.6 %)   23 (54.8 %) 24 (70.6 %)   22 (59.5 %) 11 (55 %)  
Grade 1 37 (11.7 %) 18 (10.6 %) 0.39 42 (11.1 %) 9 (6.5 %) 0.069 1 (2.4 %) 0 (0 %) 1 2 (5.4 %) 0 (0 %) 0.86
  2 120 (38 %) 56 (32.9 %)   123 (32.6 %) 59 (42.4 %)   8 (19 %) 7 (20.6 %)   6 (16.2 %) 3 (15 %)  
  3 149 (47.2 %) 92 (54.1 %)   192 (50.9 %) 64 (46 %)   32 (76.2 %) 27 (79.4 %)   26 (70.3 %) 15 (75 %)  
ER Neg 76 (24.1 %) 54 (31.8 %) 0.069 82 (21.8 %) 39 (28.1 %) 0.16 22 (52.4 %) 19 (55.9 %) 0.82 14 (37.8 %) 14 (70 %) 0.028*
  Pos 240 (75.9 %) 116 (68.2 %)   295 (78.2 %) 100 (71.9 %)   20 (47.6 %) 15 (44.1 %)   23 (62.2 %) 6 (30 %)  
Her2 Not amplified 271 (85.8 %) 139 (81.8 %) 0.29 335 (88.9 %) 123 (88.5 %) 0.87 42 (100 %) 34 (100 %) NA 37 (100 %) 20 (100 %) NA
  Amplified 45 (14.2 %) 31 (18.2 %)   41 (10.9 %) 16 (11.5 %)   20 (47.6 %) 14 (41.2 %)   24 (64.9 %) 6 (30 %)  
TP53 WT 224 (70.9 %) 110 (64.7 %) 0.076 252 (66.8 %) 94 (67.6 %) 1 20 (47.6 %) 20 (58.8 %) 0.49 7 (18.9 %) 10 (50 %) 0.011*
  Mutated 83 (26.3 %) 59 (34.7 %)   94 (24.9 %) 35 (25.2 %)   9 (21.4 %) 28 (82.4 %)   7 (18.9 %) 14 (70 %)  
IA Low 89 (28.2 %) 148 (87.1 %) 1.1×10−37* 71 (18.8 %) 111 (79.9 %) 1.5×10−37* 33 (78.6 %) 6 (17.6 %) 1.6×10−7* 30 (81.1 %) 6 (30 %) 0.00036*
  High 227 (71.8 %) 22 (12.9 %)   306 (81.2 %) 28 (20.1 %)   4 (9.5 %) 4 (11.8 %)   5 (13.5 %) 2 (10 %)  
Pam50 Basal 54 (17.1 %) 43 (25.3 %) 0.15 57 (15.1 %) 21 (15.1 %) 0.45 25 (59.5 %) 16 (47.1 %) 0.83 13 (35.1 %) 9 (45 %) 0.46
  HER2 50 (15.8 %) 18 (10.6 %)   30 (8 %) 12 (8.6 %)   5 (11.9 %) 4 (11.8 %)   7 (18.9 %) 1 (5 %)  
  LumA 106 (33.5 %) 49 (28.8 %)   129 (34.2 %) 50 (36 %)   6 (14.3 %) 7 (20.6 %)   9 (24.3 %) 4 (20 %)  
  LumB 86 (27.2 %) 48 (28.2 %)   103 (27.3 %) 28 (20.1 %)   2 (4.8 %) 3 (8.8 %)   3 (8.1 %) 4 (20 %)  
  Normal 19 (6 %) 11 (6.5 %)   58 (15.4 %) 28 (20.1 %)   42 34   37 20  
  1. Results are presented as number (%) or median (range). P-values are for Kruskal-Wallis test or Fisher’s exact test; *statistically significant. Samples with missing data are not shown. Death breast cancer-specific death, Size tumor size, Node lymph node status, Grade tumor grade, ER estrogen receptor expression status defined by gene expression data, Her2 human epidermal growth factor receptor 2 status defined by SNP6 copy number data, TP53 TP53 mutation status, WT wild type, IA immune abundance, Pam50 intrinsic subtypes, Pos positive, Neg negative, LumA luminal A, Lum B luminal B